Lishui

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

Retrieved on: 
Monday, March 20, 2023
Lishui, United, WeChat, EST, Patient, Pharmaceutical industry

and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

Key Points: 
  • and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.
  • For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

Retrieved on: 
Wednesday, October 5, 2022
LinkedIn, U.S. Securities and Exchange Commission, CD73, B-cell lymphoma, Form 20-F, Macrophage, AML, SITC, NDA, Degenerative disease, Neoplasm, MDS, Patient, Lishui, Twitter, Annual report, Myelodysplastic syndrome, Technology, Private Securities Litigation Reform Act, B cell, Tumor microenvironment, Anemia, Acute leukemia, Company, NHL, Adenosine, Safety, 2021 Essex County Council election, AMP, Intellectual property, CD47, COVID-19, WeChat, Cancer, Risk, Vaccine, Pharmaceutical industry

ET on Monday, November 7, 2022, and the posters will be available on the Company's website on November 12, 2022.

Key Points: 
  • ET on Monday, November 7, 2022, and the posters will be available on the Company's website on November 12, 2022.
  • CD47 antibody blocks this signal and enables macrophages to attack tumor cells.
  • However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells.
  • Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
Lishui, COVID-19, NDA, Technology, Safety, Degenerative disease, Anemia, Macrophage, WeChat, Myelodysplastic syndrome, Risk, AML, MDS, LinkedIn, B-cell lymphoma, Acute leukemia, NHL, U.S. Securities and Exchange Commission, Company, CD47, Cancer, Twitter, Neoplasm, Intellectual property, Annual report, Private Securities Litigation Reform Act, Form 20-F, Patient, Pharmaceutical industry

CD47 antibody blocks this signal and enables macrophages to attack tumor cells.

Key Points: 
  • CD47 antibody blocks this signal and enables macrophages to attack tumor cells.
  • However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells.
  • Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

Retrieved on: 
Friday, August 19, 2022
U.S. Securities and Exchange Commission, Lishui, Forward-looking statement, Patient, Company, Twitter, GMP, Private Securities Litigation Reform Act, Form 20-F, Annual report, LinkedIn, Terminology, WeChat, Fine chemical, Audit

GAITHERSBURG, Md. and SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022. The Company's management will host conference calls with investors to provide updates on recent pipeline development, upcoming milestones, and potential implementation of a comprehensive share purchase program by the Company and current shareholders.

Key Points: 
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • You can identify forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements.
  • Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements.
  • Actual results may differ materially from those contemplated by the forward-looking statements as a result of various important factors.

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

Retrieved on: 
Thursday, June 23, 2022
WeChat, IR, Lishui, GMP, Honor of Kings, Company, U.S. Securities and Exchange Commission, Leadership, Research, Forward-looking statement, LinkedIn, Institutional Investor (magazine), Twitter, Patient, Institution, ESG, Institutional Investor, Retail, Fine chemical, Small

The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabilities.

Key Points: 
  • The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabilities.
  • I-Mab was recognized in the "Honored Companies," "Best CEO," "Best CFO," "Best IR Professional," "Best IR Program," and "Best ESG" categories.
  • The ranking by Institutional Investor signifies capital market recognition of the Company's continued leadership in innovation and excellence in corporate governance.
  • The details of I-Mab's rankings are:
    The Company is named the "the Honored Company" in Core Asia, Mainland China and Small & Midcap results.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

Retrieved on: 
Wednesday, June 15, 2022
WeChat, Cancer, Intellectual property, NDA, Lishui, GMP, COVID-19, Safety, Neoplasm, Risk, Technology, Economics, Neutrophil, CD38, ADCP, Company, U.S. Securities and Exchange Commission, Inflammation, Forward-looking statement, Private Securities Litigation Reform Act, LinkedIn, Antigen, MDSC, ADCC, Degenerative disease, Annual report, Immune system, NASDAQ, Myeloid-derived suppressor cell, SEC, MM, Platinum, C5a, Partnership, Twitter, FSE, Patient, Autoimmunity, Terminology, Receptor (biochemistry), CDC, Form 20-F, Pharmaceutical industry, Vaccine, Greater China, MorphoSys

Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.

Key Points: 
  • Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.
  • Under the terms of the new agreements, HIBio will obtain exclusive rights to develop and commercialize felzartamab and TJ210 across all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.
  • We are excited and look forward to working together with MorphoSys and HIBio to advance clinical development and commercialization of felzartamab and TJ210," said Dr. Andrew Zhu, President of I-Mab.
  • MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize TJ210 in November 2018.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

Retrieved on: 
Wednesday, June 15, 2022
WeChat, Cancer, Intellectual property, NDA, Lishui, GMP, COVID-19, Safety, Neoplasm, Risk, Technology, Neutrophil, CD38, ADCP, Company, U.S. Securities and Exchange Commission, Inflammation, Forward-looking statement, Private Securities Litigation Reform Act, LinkedIn, Antigen, MDSC, ADCC, Degenerative disease, Annual report, Immune system, NASDAQ, Myeloid-derived suppressor cell, SEC, MM, Platinum, C5a, Partnership, Twitter, FSE, Patient, Autoimmunity, Terminology, Receptor (biochemistry), CDC, Form 20-F, Pharmaceutical industry, Vaccine, Greater China, MorphoSys

Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.

Key Points: 
  • Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.
  • Under the terms of the new agreements, HIBio will obtain exclusive rights to develop and commercialize felzartamab and TJ210 across all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.
  • We are excited and look forward to working together with MorphoSys and HIBio to advance clinical development and commercialization of felzartamab and TJ210," said Dr. Andrew Zhu, President of I-Mab.
  • MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize TJ210 in November 2018.

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Retrieved on: 
Wednesday, May 25, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Novartis, Physician, DNA, CKD, Company, General manager, International, Cardiovascular disease, PMN, Nasdaq, Transplant, Director, Degenerative disease, Patient, York University, Lishui, Therapy, KOSDAQ, BIO, TSX, Merck Serono, Bachelor of Science, Blas, Biotechnology, Board, Anemia, University, Technology, Biotechnology Innovation Organization, Head, Business, Schulich School of Business, CEO, Pharmaceutical industry, EU, Science

In 2000, Mr. Warma co-founded and later sold MedExact, a health-technology company dedicated to providing an interface between physicians and pharmaceutical companies.

Key Points: 
  • In 2000, Mr. Warma co-founded and later sold MedExact, a health-technology company dedicated to providing an interface between physicians and pharmaceutical companies.
  • Mr. Warma currently serves on the Board of ProMIS Neurosciences (TSX:PMN) and the Biotechnology Innovation Organization (BIO).
  • Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics.
  • Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

Retrieved on: 
Friday, March 18, 2022
Lishui, Company, WeChat, LinkedIn, GMP, Degenerative disease, Twitter, Patient, EST, Pharmaceutical industry, MD

The Company's mission is to bring transformational medicines to patients around the world through innovation.

Key Points: 
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability.
  • I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.
  • For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Safety, GMP, Twitter, Form 20-F, Annual report, Private Securities Litigation Reform Act, Risk, Company, CLDN6, Antibody, Immune system, U.S. Securities and Exchange Commission, Cancer, Lishui, NDA, Degenerative disease, Intellectual property, CD45, CD8, Toxicity, Patient, WeChat, Enoblituzumab, Neoplasm, Technology, COVID-19, B7, Liver, B7-H3, FC, LinkedIn, Vaccine, Pharmaceutical industry

Taken together, these data support further development of TJ-C64B towards clinical development subsequently.

Key Points: 
  • Taken together, these data support further development of TJ-C64B towards clinical development subsequently.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins.
  • B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer.
  • TJ-C64B is a bispecific antibody simultaneously targeting tumor associated antigen Claudin 6 (CLDN6) and costimulatory molecule 4-1BB for CLDN6+ tumor treatment.